Biomarkers, Neurodevelopment and Preterm Infants
Status
Conditions
Treatments
Details and patient eligibility
About
Approximately 2% of neonates in the US are born very preterm. Preterm births are associated with impaired cognitive, language and motor function, and increased risk for autism spectrum disorders. Epidemiological studies indicate a dose-response relationship between gestational age at delivery and cognitive impairments, with the most immature of newborns being the most susceptible to developmental delays. Sensitive and reproducible biomarkers of long-term neurocognitive impairments are currently lacking. The investigators seek to identify epigenetic markers that mediate the relationship between adverse prematurity-related exposures and neurocognitive impairments. The overarching hypothesis of this proposal is that DNA methylation profiles of CD34+ hematopoetic progenitor and stem cells from very preterm infants can be used as a risk-stratifying biomarker for predicting neurocognitive impairment in childhood.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- <32 weeks" gestation
- Born at Weiler Division of Montefiore
Exclusion criteria
- Intraventricular hemorrhage
- Chromosomal abnormalities
- Congenital viral conditions
Trial design
4 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal